Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copanlisib - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Copanlisib - Bayer HealthCare Pharmaceuticals

Alternative Names: 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)Aliqopa; Aliqopa; BAY-80-6946 Dihydrochloride; BAY-806946; BAY-841236; Copanlisib Dihydrochloride; Copanlisib hydrochloride

Latest Information Update: 25 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Developer All Ireland Cooperative Oncology Research Group; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb; Chonnam National University Hospital; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UNICANCER; University Hospital Muenster; University of Washington
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Morpholines; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marginal zone B-cell lymphoma; Follicular lymphoma; Waldenstrom's macroglobulinaemia; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Marginal zone B-cell lymphoma
  • Registered Non-Hodgkin's lymphoma
  • Phase II Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Endometrial cancer; Mantle-cell lymphoma; Solid tumours
  • Phase I/II Breast cancer; Colorectal cancer; HER2 positive breast cancer; Peripheral T-cell lymphoma; Squamous cell cancer
  • No development reported Lymphoma; Urogenital cancer

Most Recent Events

  • 15 Jun 2025 VA Office of Research and Development and Bayer withdraws a phase I/II trial prior to enrolment for Urogenital cancer (Adjunctive therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT05687721)
  • 10 Dec 2024 Copanlisib is still in the phase III CHRONOS-3 trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Colombia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, South Korea, Lithuania, Mexico, Malaysia, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine and Vietnam (NCT02367040)
  • 15 Nov 2024 Bayer completes the phase-III CHRONOS-3 trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Colombia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, South Korea, Lithuania, Mexico, Malaysia, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine and Vietnam (NCT02367040),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top